.jpeg)
2026-06-26 03:49:45
Fezolinetant is a novel NK3 receptor antagonist used to treat moderate to severe vasomotor symptoms (hot flashes) associated with menopause. This article provides a detailed overview of the incidence, clinical presentation, and management strategies for its common side effects, helping patients use the medication safely and effectively manage discomfort.
2026-06-26 03:21:39
Belumosudil is an oral selective ROCK2 inhibitor indicated for the treatment of chronic graft-versus-host disease (cGVHD) in patients who have failed at least two prior systemic therapies. This article provides a comprehensive overview of its efficacy data, real-world patient experiences, side effect management, and steroid-sparing effects to help patients fully understand this treatment option.
2026-06-26 03:06:36
Brivaracetam is a high-affinity SV2A ligand drug for partial-onset seizures. This article explains its mechanism, long-term use principles, discontinuation risks, evaluation criteria, tapering regimens, and special population considerations to guide safe medication discontinuation.
2026-06-25 06:42:02
Learn the principles of discontinuing mirogabalin for neuropathic pain. This guide covers physical dependence, stepwise tapering, withdrawal symptom management, and special population adjustments.
2026-06-25 06:34:59
Pretomanid is a novel anti-TB agent that kills dormant mycobacteria, enabling shorter, all-oral regimens for XDR-TB. This article covers its mechanism, BPaL trial results, safety, and clinical role.
2026-06-25 06:31:57
Tildrakizumab is a humanized monoclonal antibody targeting the IL-23 p19 subunit. This article reviews its efficacy in achieving high skin clearance rates (PASI 90/100), its favorable safety profile, convenient dosing schedule, and specific limitations regarding psoriatic arthritis and live vaccines.
2026-06-24 04:56:11
Olutasidenib is an oral selective IDH1 inhibitor approved for adult patients with relapsed or refractory acute myeloid leukemia harboring IDH1 mutations. This article covers its mechanism of action, indications, clinical efficacy data and global treatment options.
2026-06-24 04:44:34
Lusutrombopag is an oral medication indicated for thrombocytopenia in patients with chronic liver disease prior to elective invasive procedures. This guide covers standard dosage, dose adjustment, missed dose management, monitoring protocols and special population considerations.
2026-06-24 04:39:21
Gilteritinib (brand name XOSPATA) is a second-generation, highly selective FLT3 inhibitor indicated for relapsed or refractory FLT3-mutated acute myeloid leukemia. This article provides a comprehensive review of its mechanism of action, key clinical data, global access options, adverse event management and cutting-edge research progress.
2026-06-23 06:15:37
This article reviews clinical response patterns of margetuximab combined with chemotherapy for HER2-positive metastatic breast cancer, based on the Phase 3 SOPHIA trial. It details median time to response, RECIST evaluation cycles, key efficacy data, and factors influencing therapeutic outcomes.
2026-06-22 06:48:58
Brensocatib is an oral dipeptidyl peptidase-1 (DPP1) inhibitor indicated for neutrophil-mediated inflammatory diseases such as non-cystic fibrosis bronchiectasis. This article covers pre-treatment assessments, monitoring protocols, drug interactions and dosing recommendations for special populations.
2026-06-17 07:33:39
This article outlines the main adverse reaction profiles of gilteritinib, a FLT3-targeted therapy, and analyzes its safety characteristics and clinical monitoring principles from the dimensions of hematologic toxicity, organ safety risks and special differentiation syndrome.
